Biophytis and LynxKite have expanded their partnership to accelerate artificial intelligence (AI)-powered drug discovery for longevity.[1][3] The collaboration began with the MASSIVE project, which focuses on the identification and development of Mas receptor (MasR) activator drug candidates against sarcopenia, a degenerative muscle disease associated with aging.[3][5] The expansion includes new modalities beyond MASSIVE, including AI-powered drug discovery for additional longevity therapies.[1][5] The partnership will generate revenue through a longevity computing platform with unique data and accelerated methods, drug candidates against sarcopenia and dry age related macular degeneration.[1][3] LynxKite integrates advanced AI methods, chemoinformatics and scalable GPU computing on NVIDIA and Nebius platforms.[1][5] Biophytis brings expertise in age-related diseases and Mas receptor pharmacology.[5] The collaboration is supported by Enterprise Singapore and is in line with Singapore's RIE 2030 plan.[3][5]